

## SUPPLEMENTAL MATERIAL

### Supplementary Appendix Table of Contents

- 1. Table S1.** Impact of empagliflozin vs. placebo on weight, waist circumference, and indices of adiposity stratified by age at baseline in cohort 1
- 2. Table S2.** Impact of empagliflozin vs. placebo on weight, waist circumference, and indices of adiposity stratified by sex in cohort 1
- 3. Table S3.** Impact of empagliflozin vs. placebo on weight, waist circumference, and indices of adiposity stratified by degree of abdominal obesity (WC) at baseline in cohort 1

**Table S1.** Impact of empagliflozin vs. placebo on weight, waist circumference, and indices of adiposity stratified by age at baseline in cohort 1

	<50 yrs		50-64 yrs		65-74 yrs		≥75 yrs		Treatment by age P-interaction
	Placebo	Empagliflozin 10 or 25 mg	Placebo	Empagliflozin 10 or 25 mg	Placebo	Empagliflozin 10 or 25 mg	Placebo	Empagliflozin 10 or 25 mg	
<b>Body weight (kg), n</b>	31	65	154	313	79	136	7	38	0.09
Adjusted mean change from baseline <sup>†</sup>	0.3	-2.3	-0.3	-1.9	-0.1	-2.0	-1.1	-1.4	
Difference vs placebo (95% CI)		-2.6 (-3.5, -1.7)		-1.6 (-2.0, -1.2)		-1.9 (-2.5, -1.3)		-0.5 (-2.3, 1.2)	
<b>Waist circumference (cm), n</b>	31	65	154	313	79	136	7	38	0.54
Adjusted mean change from baseline <sup>†</sup>	-1.0	-1.6	-0.5	-1.5	0.5	-1.4	0.2	-1.0	
Difference vs placebo (95% CI)		-0.6 (-2.3, 1.1)		-1.1 (-1.8, -0.3)		-1.9 (-3.0, 0.8)		-1.3 (-4.4, 1.9)	
<b>Index of central obesity, n</b>	31	65	154	313	79	136	7	38	0.58
Adjusted mean change from baseline <sup>†</sup>	-0.01	-0.01	0.0	-0.01	0.0	-0.01	0.00	0.00	
Difference vs placebo (95% CI)		0.00 (-0.01, 0.01)		-0.01 (-0.01, 0.0)		-0.01 (-0.02, 0.00)		-0.01 (-0.03, 0.01)	
<b>Visceral adiposity index, n</b>	31	65	154	313	79	136	7	38	0.06
Adjusted mean change from baseline <sup>†</sup>	0.63	-0.60	0.17	0.13	0.13	-0.20	-0.31	-0.14	
Difference vs placebo (95% CI)		-1.2 (-2.0, -0.43)		-0.04 (-0.40, 0.33)		-0.32 (-0.85, 0.20)		0.17 (-1.35, 1.69)	

<sup>t</sup> Adjusted mean from ANCOVA with last observation carried forward imputation in patients randomized, received ≥1 dose of study medication, and with a baseline HbA1c value.

**Table S2.** Impact of empagliflozin vs. placebo on weight, waist circumference, and indices of adiposity stratified by sex in cohort 1

	Male		Female		Treatment by sex P-interaction
	Placebo	Empagliflozin 10 or 25 mg	Placebo	Empagliflozin 10 or 25 mg	
<b>Body weight (kg), n</b>	168	327	103	225	0.18
Adjusted mean change from baseline <sup>t</sup>	-0.1	-2.0	-0.3	-1.8	
Difference vs placebo (95% CI)		-1.9 (-2.3, -1.5)		-1.5 (-2.0, -1.0)	
<b>Waist circumference (cm), n</b>	168	327	103	225	0.53
Adjusted mean change from baseline <sup>t</sup>	-0.1	-1.2	-0.3	-1.8	
Difference vs placebo (95% CI)		-1.1 (-1.8, -0.4)		-1.5 (-2.4, -0.5)	
<b>Index of central obesity, n</b>	168	327	103	225	0.44
Adjusted mean change from baseline <sup>t</sup>	0.00	-0.01	0.00	-0.01	
Difference vs placebo (95% CI)		-0.01 (-0.01, 0.00)		-0.01 (-0.01, 0.00)	
<b>Visceral adiposity index, n</b>	168	327	103	225	0.32
Adjusted mean change from baseline <sup>t</sup>	0.02	-0.17	0.20	0.12	
Difference vs placebo (95% CI)		-0.37 (-0.72, -0.01)		-0.08 (-0.53, 0.36)	

<sup>t</sup> Adjusted mean from ANCOVA with last observation carried forward imputation in patients randomized, received ≥1 dose of study medication, and with a baseline HbA1c value.

**Table S3.** Impact of empagliflozin vs. placebo on weight, waist circumference, and indices of adiposity stratified by degree of abdominal obesity (WC) at baseline in cohort 1

	<88 cm		88-102 cm		>102 cm		Treatment by baseline WC P-interaction
	Placebo	Empagliflozin 10 or 25 mg	Placebo	Empagliflozin 10 or 25 mg	Placebo	Empagliflozin 10 or 25 mg	
<b>Body weight (kg), n</b>	10	20	69	143	190	388	0.25
Adjusted mean change from baseline <sup>t</sup>	-1.3	-1.9	-0.2	-1.7	-0.1	-2.0	
Difference vs placebo (95% CI)		-0.7 (-2.3, 1.0)		-1.5 (-2.1, -0.9)		-1.9 (-2.3, -1.5)	
<b>Waist circumference (cm), n</b>	10	20	69	143	190	388	0.89
Adjusted mean change from baseline <sup>t</sup>	1.8	1.3	0.5	-0.8	-0.6	-1.8	
Difference vs placebo (95% CI)		-0.5 (-3.5, 2.5)		-1.2 (-2.4, -0.1)		-1.3 (-2.0, -0.6)	
<b>Index of central obesity, n</b>	10	20	69	143	190	388	0.84
Adjusted mean change from baseline <sup>t</sup>	0.0	0.0	0.0	-0.01	0.0	-0.01	
Difference vs placebo (95% CI)		0.00 (-0.02, 0.02)		-0.01 (-0.01, 0.0)		-0.01 (-0.01, 0.0)	
<b>Visceral adiposity index, n</b>	10	20	69	143	190	388	0.46
Adjusted mean change from baseline <sup>t</sup>	-0.2	-0.14	0.49	-0.04	0.11	-0.05	
Difference vs placebo (95% CI)		0.06 (-1.42, 1.54)		-0.54 (-1.08, 0.00)		-0.16 (-0.49, -0.17)	

<sup>t</sup> Adjusted mean from ANCOVA with last observation carried forward imputation in patients randomized, received ≥1 dose of study medication, and with a baseline HbA1c value.